18 May 2013
Keywords: combinatorx, initiates, ph, iia, crx-401, massachusetts, usa-based
Article | 20 August 2007
Massachusetts, USA-based CombinatoRx says that it has dosed the first patient in a Phase IIa proof-of-concept clinical trial in type 2
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
20 August 2007
17 May 2013
© 2013 thepharmaletter.com